Centre Hospitalier Universitaire Hôtel-Dieu
- Address
- lock Available on a paid plan
Centre Hospitalier Universitaire Hôtel-Dieu
The Centre Hospitalier Universitaire Hôtel-Dieu is a distinguished academic medical center conducting advanced clinical research in infectious diseases, with particular expertise in HIV treatment optimization and antiretroviral therapy strategies. The center is actively engaged in innovative studies evaluating simplified treatment regimens for people living with HIV.
- HIV virological suppression and maintenance therapy studies
- Two-drug antiretroviral regimen optimization research
- Comparative effectiveness trials in HIV treatment simplification
The research team specializes in evaluating virological success outcomes and non-inferiority studies comparing novel two-drug antiretroviral combinations, including doravirine/lamivudine (DOR/3TC) and dolutegravir/lamivudine (DTG/3TC) regimens. Their work focuses on maintaining sustained viral suppression in patients with suppressed HIV plasma viral load, contributing valuable evidence to guide treatment de-escalation strategies and improve long-term therapeutic outcomes for people living with HIV.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier Universitaire Hôtel-Dieu
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Comparative Study of Doravirine/Lamivudine Versus Dolutegravir/Lamivudine for Maintenance Therapy in HIV Patients with Suppressed Viral Load | ANRS Maladies Infectieuses Emergentes, Centre De Recherches Et D'Etudes Sur La Pathologie Tropicale Et Le Sida | Phase III | Recruiting | Apr 2025 | — |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dolutegravir | 1 | Unknown | 2025-04-30 | 2025-04-30 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.